The Jackson Laboratory (JAX), a global leader in genetics and genomic medicine, has acquired the New York Stem Cell Foundation (NYSCF).
This strategic unification creates a powerful nonprofit engine for biomedical discovery, poised to accelerate the development of precision therapies for a wide range of diseases.
Key Details of the Acquisition
The acquisition, finalized on October 20, 2025, brings together two powerhouses in biomedical research. JAX is renowned for its expertise in genetics and mouse models, while NYSCF is a pioneer in stem cell research and automation technologies.
| Organization | Expertise |
| The Jackson Laboratory (JAX) | Genetics, genomic medicine, mouse models |
| New York Stem Cell Foundation (NYSCF) | Stem cell research, automation technologies |
This combination of complementary strengths will provide researchers worldwide with more advanced and predictive research platforms. The goal is to uncover disease mechanisms earlier and translate scientific discoveries into effective therapies more quickly.
Strategic Goals of the Unified Organization
The unified organization will leverage the combined expertise of JAX and NYSCF to advance the frontiers of biomedical research. The strategic goals of this acquisition are to:
•Accelerate discovery: By combining genomics, stem cell innovation, and AI, the new platform will speed up the research process from the very beginning.
•Enhance precision: The ability to investigate biology at the level of individual patients will lead to more precise and effective treatments.
•Improve reproducibility: The use of scalable stem cell platforms and high-throughput discovery will improve the reliability and reproducibility of research findings.
As Lon Cardon, president and CEO of JAX, stated, “By combining three powerful approaches – genomics, stem cell innovation, and data-driven AI – we are creating a platform that accelerates discovery from the very start of research and giving scientists stronger tools to turn early insights into breakthroughs for patients.” [1]
The Future of Biomedical Research
The integration of JAX’s genetically diverse mouse models with NYSCF’s automated stem cell array will create a powerful new platform for biomedical research. This platform will enable researchers to:
•Model human diseases more effectively: Induced pluripotent stem cells can be transformed into any cell in the body, allowing for the study of diseases like Alzheimer’s, ALS, and heart disease in a human-relevant context.
•Predict treatment responses: The platform will allow researchers to predict how different populations will respond to treatments, advancing the field of precision medicine.
•Validate research findings: Researchers will be able to test their predictions on different human cells and validate their results in whole organisms.
Daniel Paull, who now serves as JAX’s vice president of discovery and platform development, emphasized the potential of this collaboration: “Together, we can move discoveries forward earlier and with greater precision, reducing the costly failures that too often derail later-stage clinical trials.” [1]
About The Jackson Laboratory
Founded in 1929, The Jackson Laboratory (JAX) is an independent, nonprofit biomedical research institution. With a mission to discover precise genomic solutions for disease, JAX has become a global leader in genetics and genomic medicine.
The organization has nearly 3,000 employees worldwide and campuses in Maine, Connecticut, New York, California, Florida, and Japan.
About the New York Stem Cell Foundation
Established in 2005, the New York Stem Cell Foundation (NYSCF) is a pioneering nonprofit dedicated to advancing cures through stem cell research.
NYSCF has developed scalable stem cell platforms that have enabled scientists worldwide to study diseases, discover drugs, and explore the potential of regenerative medicine.
References
[1] The Jackson Laboratory. (2025, October 20). The Jackson Laboratory acquires New York Stem Cell Foundation to transform biomedical research and accelerate precision therapies for patients [Press release]. PR Newswire. https://www.prnewswire.com/news-releases/the-jackson-laboratory-acquires-new-york-stem-cell-foundation-to-transform-biomedical-research-and-accelerate-precision-therapies-for-patients-302588940.html
